完整後設資料紀錄
DC 欄位語言
dc.contributor.authorCheng, Chun-Wenen_US
dc.contributor.authorWang, Hsiao-Weien_US
dc.contributor.authorChang, Chia-Weien_US
dc.contributor.authorChu, Hou-Weien_US
dc.contributor.authorChen, Cheng-Youen_US
dc.contributor.authorYu, Jyh-Cherngen_US
dc.contributor.authorChao, Jui-Ien_US
dc.contributor.authorLiu, Huei-Fangen_US
dc.contributor.authorDing, Shian-lingen_US
dc.contributor.authorShen, Chen-Yangen_US
dc.date.accessioned2014-12-08T15:23:47Z-
dc.date.available2014-12-08T15:23:47Z-
dc.date.issued2012-08-01en_US
dc.identifier.issn0167-6806en_US
dc.identifier.urihttp://hdl.handle.net/11536/16599-
dc.description.abstract"Tumor recurrence and metastasis result in an unfavorable prognosis for cancer patients. Recent studies have suggested that specific microRNAs (miRNAs) may play important roles in the development of cancer cells. However, prognostic markers and the outcome prediction of the miRNA signature in breast cancer patients have not been comprehensively assessed. The aim of this study was to identify miRNA biomarkers relating to clinicopathological features and outcome of breast cancer. A miRNA microarray analysis was performed on breast tumors of different lymph node metastasis status and with different progression signatures, indicated by overexpression of cyclin D1 and beta-catenin genes, to identify miRNAs showing a significant difference in expression. The functional interaction between the candidate miRNA, miR-30a, and the target gene, Vim, which codes for vimentin, a protein involved in epithelial-mesenchymal transition, was examined using the luciferase reporter assay, western blotting, and migration and invasion assays. The association between the decreased miR-30a levels and breast cancer progression was examined in a survival analysis. miR-30a negatively regulated vimentin expression by binding to the 3'-untranslated region of Vim. Overexpression of miR-30a suppressed the migration and invasiveness phenotypes of breast cancer cell lines. Moreover, reduced tumor expression of miR-30a in breast cancer patients was associated with an unfavorable outcome, including late tumor stage, lymph node metastasis, and worse progression (mortality and recurrence) (p < 0.05). In conclusion, these findings suggest a role for miR-30a in inhibiting breast tumor invasiveness and metastasis. The finding that miR-30a downmodulates vimentin expression might provide a therapeutic target for the treatment of breast cancer."en_US
dc.language.isoen_USen_US
dc.subjectBreast canceren_US
dc.subjectMicroRNA-microarrayen_US
dc.subjectMiR-30aen_US
dc.subjectVimentinen_US
dc.subjectPrognosisen_US
dc.titleMicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast canceren_US
dc.typeArticleen_US
dc.identifier.journalBREAST CANCER RESEARCH AND TREATMENTen_US
dc.citation.volume134en_US
dc.citation.issue3en_US
dc.citation.epage1081en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000307273300016-
dc.citation.woscount40-
顯示於類別:期刊論文


文件中的檔案:

  1. 000307273300016.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。